Cellectis And Imagine Institute Publish A Proof-Of-Concept Study Of A Gene Surgery Candidate To Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1
Portfolio Pulse from Benzinga Newsdesk
Cellectis and Imagine Institute have published a proof-of-concept study of a gene surgery candidate to treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1). The preclinical results demonstrated that the PIK3CD gene can be efficiently corrected by TALEN®-mediated gene insertion, rescuing PI3K signaling and normalizing the transcriptomic status of APDS1 patient CD8+ T-cells.
October 12, 2023 | 8:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis' gene surgery candidate shows promise in treating APDS1, according to a proof-of-concept study. This could potentially open up a new therapeutic area for the company.
The news is directly related to Cellectis' research and development efforts. If the gene surgery candidate proves successful in further studies, it could potentially lead to a new product for the company, positively impacting its stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100